Genomic Vision: Availability of the universal registration document

BAGNEUX, France, April 15, 2022–(BUSINESS WIRE)–Regulatory News:

Genomic Vision (FR0011799907 – GV, PEA-PME eligible) (Paris:GV), a biotechnology company that develops tools and services dedicated to the analysis and control of genome modifications, announces today that it has made available to the public and filed with the Autorité des marchés financiers its universal registration document for the 2020 financial year.

The document, filed on April 14 with the Autorité des Marchés Financiers, is available to the public free of charge under the conditions provided for by the regulations in force and can be consulted on the company’s website at the address www.genomicvision.comsection Investors / Regulated information as well as that of the AMF (www.amf-france.org).

It includes in particular the half-year financial statements as of June 30, 2021, the 2020 annual financial report, the report of the Supervisory Board on corporate governance and the reports of the Statutory Auditors.

***

ABOUT GENOMIC VISION

GENOMIC VISION is a biotechnology company that develops products and services dedicated to the analysis (structural and functional) of genome modifications as well as to the quality and safety control of these modifications, in particular in the technologies of editing of the genome and in bioproduction processes. GENOMIC VISION’s proprietary tools based on DNA combing technology and artificial intelligence, provide robust quantitative measurements needed for reliable characterization of DNA alterations in the genome. These tools are notably used to monitor DNA replication in cancer cells, for the early detection of cancers and for the diagnosis of genetic diseases. Based in Bagneux, in the Paris region, GENOMIC VISION is listed on the regulated Euronext market in Paris, Compartment C (Euronext: GV – ISIN: FR0011799907).

www.genomicvision.com

***

Index Member CAC® Mid & Small and CAC® All-Tradable

WARNING

This press release contains implicitly or expressly forward-looking statements relating to Genomic Vision and its activities. Genomic Vision believes that these forward-looking statements are based on reasonable assumptions. However, no guarantee can be given as to the achievement of the forecasts expressed in these forward-looking statements which are subject to risks, including those described in the “Risk Factors” section of the Universal Registration Document filed with the Autorité des Marchés Financiers (AMF) on April 14, 2022, under number D. 22-0293, which is available on the Company’s website (www.genomicvision.com) and changes in economic conditions, financial markets and markets in which Genomic Vision is present. The forward-looking statements contained in this press release are also subject to risks unknown to Genomic Vision or that Genomic Vision does not consider material at this date. The realization of all or part of these risks could cause the actual results, financial conditions, performance or achievements of Genomic Vision to differ materially from the results, financial conditions, performances or achievements expressed in these forward-looking statements.

This press release and the information it contains do not constitute, nor shall they be interpreted as an offer or invitation to sell or subscribe, or the solicitation of any order or invitation to buy or subscribe to Genomic Vision shares. in any country. The distribution of this press release in certain countries may constitute a violation of the legal provisions in force. Persons in possession of the press release must therefore inform themselves of any local restrictions and comply with them.

View the source version on businesswire.com: https://www.businesswire.com/news/home/20220415005110/en/

contacts

Genomic Vision
Dominique Remy-Renou
President of the Management Board
Such. : +33 1 49 08 07 51
investors@genomicvision.com

Ulysses Communication
Press relations
Bruno Arabian
Such. : +33 1 42 68 29 70
barabian@ulysse-communication.com

NewCap
Investor Relations
& Strategic Communications
Such. : +33 1 44 71 94 94
gv@newcap.eu

We would like to say thanks to the author of this article for this awesome material

Genomic Vision: Availability of the universal registration document


Check out our social media profiles as well as other related pageshttps://www.ai-magazine.com/related-pages/